New lupus drug tracked in global real-world study
NCT ID NCT06314282
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 3 times
Summary
This study follows 200 adults with lupus who are starting anifrolumab for the first time, to see how well it works in everyday clinics. Researchers will measure disease activity, skin symptoms, fatigue, and quality of life over time. The goal is to provide real-world evidence to help doctors, insurers, and patients make informed treatment decisions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
ACTIVE_NOT_RECRUITINGBuenos Aires, Argentina
-
Research Site
ACTIVE_NOT_RECRUITINGCórdoba, Argentina
-
Research Site
WITHDRAWNGuangzhou, China
-
Research Site
ACTIVE_NOT_RECRUITINGHong Kong, China
-
Research Site
WITHDRAWNShenzhen, China
-
Research Site
ACTIVE_NOT_RECRUITINGZhongshan, China
-
Research Site
WITHDRAWNZhuhai, China
-
Research Site
ACTIVE_NOT_RECRUITINGSan José, Costa Rica
-
Research Site
RECRUITINGAlexandria, Egypt
-
Research Site
RECRUITINGCairo, Egypt
-
Research Site
ACTIVE_NOT_RECRUITINGGuatemala City, Guatemala
-
Research Site
ACTIVE_NOT_RECRUITINGAktobe, Kazakhstan
-
Research Site
ACTIVE_NOT_RECRUITINGAlmaty, Kazakhstan
-
Research Site
WITHDRAWNAlmaty, Kazakhstan
-
Research Site
ACTIVE_NOT_RECRUITINGAstana, Kazakhstan
-
Research Site
WITHDRAWNAstana, Kazakhstan
-
Research Site
ACTIVE_NOT_RECRUITINGPavlodar, Kazakhstan
-
Research Site
ACTIVE_NOT_RECRUITINGSemey, Kazakhstan
-
Research Site
ACTIVE_NOT_RECRUITINGShymkent, Kazakhstan
-
Research Site
RECRUITINGKuwait City, Kuwait
-
Research Site
RECRUITINGMexico City, Mexico
-
Research Site
RECRUITINGMérida, Mexico
-
Research Site
ACTIVE_NOT_RECRUITINGMuscat, Oman
-
Research Site
ACTIVE_NOT_RECRUITINGDoha, Qatar
-
Research Site
ACTIVE_NOT_RECRUITINGASIR, Saudi Arabia
-
Research Site
ACTIVE_NOT_RECRUITINGJeddah, Saudi Arabia
-
Research Site
ACTIVE_NOT_RECRUITINGRiyadh, Saudi Arabia
-
Research Site
ACTIVE_NOT_RECRUITINGKaohsiung City, Taiwan
-
Research Site
ACTIVE_NOT_RECRUITINGTaichung, Taiwan
-
Research Site
WITHDRAWNTaichung, Taiwan
-
Research Site
ACTIVE_NOT_RECRUITINGTaipei, Taiwan
-
Research Site
ACTIVE_NOT_RECRUITINGTaoyuan, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Eye tests could spot silent vision damage in lupus patients
- Could a simple blood test predict lupus in children with ITP?
- Can an extra shot boost COVID protection in autoimmune patients?
- Can a blood test predict lupus flares? new study aims to find out
- Tiny study aims to predict lupus flares before they strike
- Real-World lupus study reveals how new drug performs outside clinical trials